Variable | Total (n = 8309) | Treatment duration  ≤ 24 months (n = 4275) | Treatment duration  > 24 months (n = 4034) | P value | |
---|---|---|---|---|---|
Treatment duration (months) | 24.00 (11.00–44.00) | 11.00 (5.00–17.00) | 46.00 (35.00–62.00) | – | |
ETV, n(%) | 5960 (71.73) | 2904 (67.93) | 3056 (75.76) |  < 0.001 | |
TDF, n(%) | 1348 (16.22) | 1015 (23.74) | 333 (8.25) |  < 0.001 | |
Others, n(%) | 1001 (12.05) | 356 (8.33) | 645 (15.99) |  < 0.001 | |
LAM exposure, n(%) | 1094 (13.17) | 77 (1.80) | 1017 (25.21) |  < 0.001 | |
Nucleotide analogue exposure n(%) | 2556 (30.76) | 1211 (28.33) | 1345 (33.34) |  < 0.001 |